Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
PD-L1-high non-small-cell lung cancer without a driver mutation
Data

Cancers·PD-L1-high non-small-cell lung cancer without a driver mutation

DataPD-L1-high non-small-cell lung cancer without a driver mutation

Back to the PD-L1-high non-small-cell lung cancer without a driver mutation hub →98 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

98

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
HER2-mutant non-small-cell lung cancer
Shares KEYNOTE-024 & KEYNOTE-189, BRAF V600E-mutant non-small-cell lung cancer, Non-small cell lung cancer (KEGG map), ALK-positive non-small-cell lung cancer and the tags subtype-page, lung.
Cancer
MET exon 14 and MET-amplified non-small-cell lung cancer
Shares BRAF V600E-mutant non-small-cell lung cancer, Adenocarcinoma of the lung, Non-small cell lung cancer (KEGG map), ALK-positive non-small-cell lung cancer and the tags subtype-page, lung.
Cancer
NTRK fusion-positive non-small-cell lung cancer
Shares BRAF V600E-mutant non-small-cell lung cancer, Non-small cell lung cancer (KEGG map), ALK-positive non-small-cell lung cancer, Roche / Genentech and the tags subtype-page, lung.
Cancer
RET fusion-positive non-small-cell lung cancer
Shares BRAF V600E-mutant non-small-cell lung cancer, Non-small cell lung cancer (KEGG map), ALK-positive non-small-cell lung cancer, Roche / Genentech and the tags subtype-page, lung.
Cancer
ROS1-positive non-small-cell lung cancer
Shares BRAF V600E-mutant non-small-cell lung cancer, Non-small cell lung cancer (KEGG map), ALK-positive non-small-cell lung cancer, Roche / Genentech and the tags subtype-page, lung.
Cancer
Extensive-stage small-cell lung cancer
Shares Martin Reck, Maintenance therapy, PD-1 / PD-L1 immune checkpoint & T-cell activation, Atezolizumab and the tags subtype-page, lung.
Cancer
Limited-stage small-cell lung cancer
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Carboplatin, Immune checkpoint inhibitors and the tags subtype-page, lung.
Cancer
Large cell neuroendocrine carcinoma of the lung
Shares Non-small-cell lung cancer and the tags subtype-page, lung.

technologies

Anti-angiogenic therapy Antibody-drug conjugate (ADC)Bispecific antibodies Companion diagnostics Cytotoxic chemotherapy Histopathology & immunohistochemistry Immune checkpoint inhibitors Monoclonal antibodies MRD / molecular residual disease testing Platinum agents Topoisomerase-I inhibitors (and ADC payloads)

targets

CTLA-4 PD-1 PD-L1 TROP2 VEGF / VEGFR

drugs

ApprovedMonoclonal antibody (anti-PD-L1)

Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)

ApprovedCytotoxic chemotherapy (platinum)

ApprovedMonoclonal antibody (anti-PD-1)

Cemiplimab · Libtayo

ApprovedADC

Datopotamab deruxtecan · Datroway

ApprovedCytotoxic chemotherapy (taxane)

Docetaxel · Taxotere (generic)

ApprovedMonoclonal antibody (anti-CTLA-4)

Ipilimumab · Yervoy

ApprovedBispecific antibody (PD-1×VEGF)

ApprovedMonoclonal antibody (anti-PD-1)

Nivolumab · Opdivo / Opdivo Qvantig (SC)

ApprovedCytotoxic chemotherapy (taxane)

Paclitaxel / nab-paclitaxel · Taxol / Abraxane

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

ApprovedCytotoxic (antifolate)

Pemetrexed · Alimta (and generics)

ApprovedMonoclonal antibody (anti-VEGFR2)

Ramucirumab · Cyramza

ApprovedADC

Sacituzumab tirumotecan

ApprovedPD-L1 immunohistochemistry companion diagnostic assay

VENTANA PD-L1 (SP142) Assay · VENTANA PD-L1 (SP142)

companies

Akeso AstraZeneca Bristol Myers Squibb Chugai Pharmaceutical CSPC Pharmaceutical Group Daiichi Sankyo Eli Lilly (incl. Loxo)Merck & Co. (MSD)Regeneron Roche / Genentech Sanofi Sichuan Kelun-Biotech Summit Therapeutics

institutions

LungenClinic Grosshansdorf

pathways

Non-small cell lung cancer (KEGG map)PD-1 / PD-L1 immune checkpoint & T-cell activation

terms

Immune checkpoint Immuno-oncology (IO) and checkpoint blockade Maintenance therapy PD-L1 expression testing (22C3, SP142, SP263)Tumour proportion score (TPS)

trials

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden CheckMate 026 CheckMate 227 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 EMPOWER-Lung 1 HARMONi-2 HARMONi-3 IMpower110 KEYNOTE-010 KEYNOTE-024 & KEYNOTE-189 KEYNOTE-042 KEYNOTE-407 Lung-MAP S1800A: ramucirumab plus pembrolizumab PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu TROPION-Lung01 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

pairings

PD-1 blockade + chemotherapy in PD-L1-low NSCLC

ideas

Use a blood test at six weeks to decide whether to keep going

people

Julie R. Brahmer Martin Reck Matthew D. Hellmann Roy S. Herbst Solange Peters Tony S. K. Mok

key papers

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file

Wikipedia

Sources & links

Wikipedia
NCCN Guidelines: Non-Small Cell Lung Cancer

subtype-page lung

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of PD-L1-high non-small-cell lung cancer without a driver mutation

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/pdl1-high-nsclc/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id pdl1-high-nsclc.

WebMCP tools registered on this page: onco_search, onco_get_entity.